Intuitive Surgical Reports 19% Revenue Growth to $2.9 Billion in Q4 2025

Written by Emily J. Thompson, Senior Investment Analyst

ISRG+0.4%

Source: Fool

Updated: 1h ago

0mins

Source: Fool

Significant Revenue Growth: Intuitive Surgical reported a 19% year-over-year revenue increase in Q4 2025, reaching $2.9 billion, with net income rising from $686 million to $795 million, reflecting strong financial performance and market demand.
Sustained Procedure Volume: Worldwide procedures grew 18% year-over-year, with Da Vinci platform procedures increasing by 17% and Ion procedures soaring by 44%, enhancing both service and accessory revenue while strengthening competitive positioning in the medical device market.
Strong System Sales: The company installed 532 Da Vinci systems in Q4, including 303 of the latest Da Vinci 5 systems, resulting in a 12% increase in the installed base to 11,106 systems for the year, demonstrating ongoing expansion in the surgical robotics sector.
Robust Financial Profile: By the end of 2025, Intuitive Surgical reported approximately $9 billion in cash and investments with no debt, providing substantial financial support for future business expansion and competitive positioning.

ISRG

$525.81+Infinity%1D

Analyst Views on ISRG

Wall Street analysts forecast ISRG stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ISRG is 637.32 USD with a low forecast of 575.00 USD and a high forecast of 740.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

20 Analyst Rating

16 Buy

4 Hold

0 Sell

Strong Buy

Current: 523.690

Low

575.00

Averages

637.32

High

740.00

Current: 523.690

Low

575.00

Averages

637.32

High

740.00

Goldman Sachs

NULL -> Buy

maintain

$621 -> $714

2026-01-09

Reason

Goldman Sachs

Price Target

$621 -> $714

AI Analysis

2026-01-09

maintain

NULL -> Buy

Reason

Goldman Sachs raised the firm's price target on Intuitive Surgical to $714 from $621 and keeps a Buy rating on the shares. After a year when fundamentals diverged from stock performance, 2026 should represent a return to normalized patterns where organic growth defines relative valuation, the analyst tells investors in a research note.

Bernstein

Outperform

maintain

$700 -> $740

2026-01-09

Reason

Bernstein

Price Target

$700 -> $740

2026-01-09

maintain

Outperform

Reason

Bernstein raised the firm's price target on Intuitive Surgical to $740 from $700 and keeps an Outperform rating on the shares. After a low point in September 2025, U.S. healthcare stocks have begun to perform better over the past several months, the firm notes. As the market gets more clarity on many of the macro / policy uncertainties that weighed on healthcare stocks during the course of 2025, Bernstein anticipates better days ahead for healthcare stocks in 2026.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for ISRG

Unlock Now

BTIG

Buy

maintain

$589 -> $616

2026-01-08

Reason

BTIG

Price Target

$589 -> $616

2026-01-08

maintain

Buy

Reason

BTIG raised the firm's price target on Intuitive Surgical to $616 from $589 and keeps a Buy rating on the shares. Analysis of the Dv5 launch suggests its value extends beyond higher system average selling prices, with the growing install base also driving incremental I&A revenue through increased utilization and new procedures, the analyst tells investors in a research note. Based on management commentary and Street assumptions, Dv5 is estimated to account for about 25% of modeled FY26 revenue growth and roughly 35% in FY27, with its impact better understood by examining contributions across both System and I&A revenue rather than topline alone, the firm says.

BTIG

Buy

maintain

$589 -> $616

2026-01-07

Reason

BTIG

Price Target

$589 -> $616

2026-01-07

maintain

Buy

Reason

BTIG raised the firm's price target on Intuitive Surgical to $616 from $589 and keeps a Buy rating on the shares. Analysis of the Dv5 launch suggests it accounts for roughly 25.3% of Street-modeled revenue growth in FY26 and 34.5% in FY27, the analyst tells investors in a research note. While this may appear low given the launch's strategic importance, a deeper look at its impact on both System and Instruments & Accessories revenue provides a fuller view of its contribution to overall growth, BTIG says.

About ISRG

Intuitive Surgical, Inc. develops, manufactures, and markets da Vinci surgical systems and the Ion endoluminal system. The Company specializes in invasive care and robotic-assisted surgery. Its technologies include the da Vinci surgical systems and the Ion endoluminal system. The da Vinci surgical system is designed to enable surgeons to perform a range of surgical procedures within its targeted general surgery, urologic, gynecologic, cardiothoracic, and head and neck specialties and consists of a surgeon's console or consoles, a patient-side cart, and a high-performance vision system. The Ion endoluminal system is a flexible, robotic-assisted, catheter-based platform for which the cleared indication is minimally invasive biopsies in the lung and consists of a system cart, a controller, a catheter, and a vision probe. Its Ion system extends its commercial offering beyond surgery into diagnostic and endoluminal procedures.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.